Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Stoke Therapeutics Inc shares valued at $52,379 were sold by Ticho Barry on Jul 01 ’25. At $11.63 per share, Ticho Barry sold 4,503 shares. The insider’s holdings dropped to 21,279 shares worth approximately $0.27 million following the completion of this transaction.
Also, BARUCH TICHO purchased 9,007 shares, netting a total of over 102,229 in proceeds.
Before that, Skorpios Trust had sold 3,000,000 shares from its account. In a trade valued at $30,600,000, the 10% Owner traded Stoke Therapeutics Inc shares for $10.20 each. Upon closing the transaction, the insider’s holdings decreased to 3,000,000 shares, worth approximately $50.27 million.
As published in their initiating research note from Jefferies on July 18, 2025, Stoke Therapeutics Inc [STOK] has been a Buy and the price target has been revised to $30. Analysts at Chardan Capital Markets started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. Earlier on March 26, 2024, TD Cowen upgraded its rating. Their new recommendation was “an Outperform” for STOK stock which previously was a “a Market perform”.
Analyzing STOK Stock Performance
On last trading session,, Stoke Therapeutics Inc [NASDAQ: STOK] rose 2.96% to $12.87. The stock’s lowest price that day was $12.61, but it reached a high of $13.12 in the same session. During the last five days, there has been a drop of approximately -9.81%. Over the course of the year, Stoke Therapeutics Inc shares have dropped approximately -18.85%.
Support And Resistance Levels for Stoke Therapeutics Inc (STOK)
RSI (Relative Strength Index) is 55.63 on the 14-day chart, showing neutral technical sentiment.
Is Stoke Therapeutics Inc subject to short interest?
Stocks of Stoke Therapeutics Inc saw a sharp steep in short interest on 2025-07-15 dropping by -0.61 million shares to 11.5 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 12.11 million shares. A decline of -5.32% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 20.19 of the overall float, the days-to-cover ratio (short ratio) decline to 20.19.
Which companies own the most shares of Stoke Therapeutics Inc (STOK)?
In terms of Stoke Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 76.0% from the previous closing price of $12.5. Analysts anticipate Stoke Therapeutics Inc stock to reach 58 by 2025, with the lowest price target being 18. In spite of this, 5 analysts ranked Stoke Therapeutics Inc stock as Buy at the end of 2025.
